Morgan Stanley assumed coverage of Grail (GRAL) with an Equal Weight rating and a price target of $38, up from $20. While the firm sees significant long-term potential for Grail’s Galleri MCED test, there are also inherent risks associated with novel technologies from a regulatory and reimbursement standpoint, the analyst tells investors. The firm is also updating estimates for Q1 results, noting that its Q2 and 2025 revenue estimates move to $36M and $151M, from prior forecasts of $37M and $149M, respectively.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Cautious Optimism for GRAIL Inc: Hold Rating Amid Early Market Position and Future Milestones
- Grail reports results from PATHFINDER 2 study
- NINGI short Grail, says ‘approval and commercialization all but impossible’
- GRAIL Inc Holds Annual Stockholders Meeting
- Grail Inc. Q1 Earnings: Growth Amid Funding Concerns